3//SEC Filing
Decheng Capital China Life Sciences USD Fund III, L.P. 3
Accession 0001209191-19-005067
CIK 0001626199other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 8:45 PM ET
Size
8.0 KB
Accession
0001209191-19-005067
Insider Transaction Report
Form 3
Holdings
- 3,165,735(indirect: See Footnote)
Common Stock
- (indirect: See Footnote)
Warrant (right to buy)
Exercise: $12.74From: 2019-01-18Exp: 2024-01-18→ Common Stock (1,234,636 underlying)
Footnotes (2)
- [F1]The reportable securities are included within 3,165,735 units representing (i) 3,165,735 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), and (ii) warrants to purchase an additional 1,234,636 shares of Common Stock for $5.37 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.39 of a share of Common Stock).
- [F2]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001736814
Filing Metadata
- Form type
- 3
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 8:45 PM ET
- Size
- 8.0 KB